Study Endpoints

Primary Endpoint

Change in proteinuria after 1 year of treatment

Secondary Endpoints

Creatinine clearance
Surrogate renal protection endpoints (i.e., estimated glomerular filtration rate [eGFR])
Change in asymmetric dimethylarginine and high sensitive C-reactive protein levels
Composite of morbidity and mortality from CV causes
Measures of endothelial dysfunction and further metabolic parameters